Drug Profile
Research programme: anti-CA19-9 monoclonal antibody - Quest PharmaTech
Alternative Names: Anti-CA19.9 monoclonal antibody - Quest PharmaTech; AR44.6; GivaRexLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ViRexx Medical Corp
- Developer Quest PharmaTech
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastrointestinal cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gastrointestinal-cancer in USA (IV)
- 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
- 23 Jul 2013 Quest PharmaTech enters a long-term strategic agreement with AD Biotech to co-develop research and technologies of both companies